

# Tigecycline Antibacterial Activity in Current (2004-06) Global Population - An Age Population Analysis - T.E.S.T. Program 2006

S. Bouchillon<sup>1</sup>, T. Stevens<sup>1</sup>, J. Johnson<sup>1</sup>, D. Hoban<sup>1</sup>, R. badal<sup>1</sup>, B. Johnson<sup>1</sup>, M. Dowzicky<sup>2</sup>

<sup>1</sup>International Health Management Associates, Schaumburg, IL, USA  
<sup>2</sup>Wyeth Pharmaceuticals, Collegeville, PA, USA

IHMA, Inc.  
2122 Palmer Dr.  
Schaumburg, IL 60173  
Tel: (847) 303-5003  
Fax: (847) 303-5601  
www.ihmainc.com

#E-0731

## REVISED ABSTRACT

**Background:** Tigecycline (TIG), a new glycolcycline, has been shown to have potent broad spectrum activity against most commonly encountered species responsible for community and hospital acquired infections. The T.E.S.T. program determined the in vitro activity of TIG and 10 comparators against respective gram positive/negative species. Isolates were collected from 213 hospital sites in 32 countries from 2004 to 2006. **Methods:** Over 38,000 clinically significant isolates collected worldwide were analyzed in this survey. The isolates were identified to the species level at the participating sites and confirmed by the central laboratory. MICs were determined by each site using supplied broth microdilution panels and interpreted according to CLSI guidelines. **Results:** Selected pathogens tested against tigecycline are shown in the table below:

		Tigecycline		
		n	%S	MIC <sub>90</sub>
Pediatric (0-13)	Enterobacteriaceae	1470	97.9	1
	<i>Acinetobacter</i> spp.	202	n/a	1
	<i>S. aureus</i>	485	99.9	0.25
	<i>S. pneumoniae</i>	613	n/a	0.5
Young Adult (14-29)	Enterobacteriaceae	1367	97.8	1
	<i>Acinetobacter</i> spp.	275	n/a	1
	<i>S. aureus</i>	539	99.8	0.25
	<i>S. pneumoniae</i>	192	n/a	1
Adult (30-64)	Enterobacteriaceae	6448	96.2	1
	<i>Acinetobacter</i> spp.	1205	n/a	1
	<i>S. aureus</i>	2213	99.1	0.25
	<i>S. pneumoniae</i>	1126	n/a	0.5
Geriatric (65+)	Enterobacteriaceae	6611	95.7	1
	<i>Acinetobacter</i> spp.	950	n/a	1
	<i>S. aureus</i>	1688	99.2	0.25
	<i>S. pneumoniae</i>	813	n/a	0.5

n/a = breakpoints not available

**Conclusion:** Tigecycline showed excellent inhibitory activity against all groups of pathogens regardless of age group. Tigecycline MIC<sub>90</sub> of 0.25mcg/ml and 0.5mcg/ml against *S. aureus* and *S. pneumoniae*, respectively, and MIC<sub>90</sub> of 1mcg/ml against *Enterobacteriaceae* and *Acinetobacter* spp. validate the potent inhibitory activity of TIG against community/hospital pathogens in all age populations.

## INTRODUCTION

Tigecycline is the first marketed glycolcycline with expanded broad-spectrum activity against both aerobic and anaerobic pathogens. Tigecycline inhibits protein synthesis by binding to the 30S ribosomal subunit. Although it is perceived to be bacteriostatic, its anti-bacterial activity is significant and has shown some bactericidal activity against key targeted pathogens [1,2]. Tigecycline was developed to provide activity against tetracycline- and multi-drug-resistant pathogens and has demonstrated significant activity against aerobic and anaerobic Gram-positive and Gram-negative microorganisms [2-4].

Tigecycline resistance is very infrequent and is also difficult to induce in the laboratory [5, 6] with a selection frequency of less than 10<sup>-9</sup> observed [3, 5]. With the exception of *Pseudomonas aeruginosa*, tetracycline-resistant bacteria with either tetracycline efflux pumps or ribosomal protective features are sensitive to tigecycline [2-4]. Tigecycline has demonstrated MIC<sub>90</sub> values of ≤0.5 mcg/ml against methicillin-resistant *Staphylococcus aureus* (MRSA) and other Gram-positive organisms [2, 4-6]. Tigecycline has shown potent activity in animal models infected with selected strains of multi-drug resistant *Enterococcus faecium* and *Enterococcus faecalis* [4, 5] with diverse genotypes van-A, -B and -C [6].

Tigecycline has now been tested on large numbers of diverse demographic and geographic populations. This study documents the in vitro activity of tigecycline against these diverse populations segregated by age. Since tigecycline has shown no age related pharmacokinetic parameters and few, if any, inconsistencies within species, mostly without regard to resistant phenotypes, consistency in activity across various age groups is postulated and the consistency of activity for different age groups is explored across various species and organism groups.

## MATERIALS & METHODS

All isolates were derived from blood, respiratory tract, urine (no more than 25% of all isolates), skin, wound, body fluids, and other defined sources. Only one isolate per patient was accepted into the study. Clinical isolates were collected from 213 medical centers in 32 countries and tested between 2004 to 2006. Isolates were identified to the species level and tested at each site by the participating laboratory.

Organism collection, transport, confirmation of organism identification, and development and management of a centralized database, were coordinated by Laboratories International for Microbiology Studies (LIMS), a division of International Health Management Associates, Inc. located in Schaumburg, IL, USA.

All organisms were deemed clinically significant by local participant criteria. Isolate inclusion was independent of medical history, antimicrobial use, age, or gender. All sites identified each study isolate utilizing local laboratory criteria.

Minimum inhibitory concentrations (MICs) were determined by the CLSI recommended broth microdilution testing method [7]. Tigecycline was supplied by Wyeth Pharmaceuticals (Collegeville, PA, USA). All other agents were supplied by the panel manufacturer, MicroScan (Dade Behring Inc., Sacramento, CA, USA). The following antimicrobial agents were included on the panels with their dilution ranges (expressed in mcg/ml): amikacin (0.5-64); amoxicillin/clavulanic acid (0.12/0.06-32/16); ampicillin (0.5-32, gram-negative panel, and 0.06-16, gram-positive panel); cefepime (0.5-32); ceftriaxone (0.06-64); ceftazidime (8-32); imipenem (0.06-16); linezolid (0.5-8); levofloxacin (0.008-8); minocycline (0.5-16); tigecycline (0.008-16); penicillin (0.06-8); piperacillin/tazobactam (0.06/4-128/4) and vancomycin (0.12-32). MIC interpretive criteria followed published guidelines established by the Clinical and Laboratory Standards Institute [8] and the recent US Food and Drug Administration package insert for tigecycline [9], where applicable.

Quality controls (QC) were performed by each testing site on each day of testing using the corresponding ATCC control strains: *E. coli* ATCC 25922; *E. coli* ATCC 35218; *H. influenzae* ATCC 49766; *H. influenzae* ATCC 49247; *S. aureus* ATCC 29213; *Pseudomonas aeruginosa* ATCC 27853; *Enterococcus faecalis* ATCC 29212 and *S. pneumoniae* ATCC 49619. Results were included in the analysis only when corresponding QC isolates tested within the acceptable range according to CLSI (2005) guidelines [8].

## REFERENCES

- Sum, P.E. and P. Petersen, *Synthesis and structure-activity relationship of novel glycolcycline derivatives leading to the discovery of GAR-936*. Bioorg Med Chem Lett, 1999, 9(10): p. 1459-62.
- Abbanat, D., M. Macielag, and K. Bush, *Novel antibacterial agents for the treatment of serious Gram-positive infections*. Expert Opin Investig Drugs, 2003, 12(3): p. 379-99.
- Betriu, C., et al., *In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain*. Antimicrob Agents Chemother, 2002, 46(3): p. 892-5.
- Gales, A.C. and R.N. Jones, *Antimicrobial activity and spectrum of the new glycolcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates*. Diagn Microbiol Infect Dis, 2000, 36(1): p. 19-36.
- Henwood, C.J., et al., *Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)*. J Antimicrob Chemother, 2002, 49(3): p. 479-87.
- Chopra, I., *New developments in tetracycline antibiotics: glycolcyclines and tetracycline efflux pump inhibitors*. Drug Resist Updat, 2002, 5(3-4): p. 119-25.
- CLSI. *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically*; Approved Standard-Sixth Edition, in Document M7-A6. 2005; Clinical Laboratory Standards Institute (CLSI), 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
- CLSI. *Performance Standards for Antimicrobial Susceptibility Testing*, in Document M100-S15. 2005; Clinical Laboratory Standards Institute (CLSI), 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
- Tygacil, *Product Insert*. 2005; Wyeth Pharmaceuticals, Inc., Philadelphia, PA, USA.

## ACKNOWLEDGEMENTS

We gratefully acknowledge the contributions of the investigators, laboratory personnel, and all members of the Tigecycline Evaluation Study Trials program group. This study was sponsored by a grant from Wyeth Pharmaceuticals.

## RESULTS

Table 1. Frequency Distribution of Age Groups for All Isolates\*

Age Group	Total N	% of Total
Pediatric (NB-13)	3,723	11.20%
Young Adult (14-29)	3,238	9.70%
Adult (30-64)	13,902	41.90%
Geriatric (65+)	12,355	37.20%
Total	33,218	100.00%

\* *Pseudomonas aeruginosa* is excluded from all analyses as well as all isolates having no age given.

Table 2. Statistical Analysis of Tigecycline MIC values by Age Groups for all Study Organisms Combined.

	Quartile MIC (mcg/mL)						t-Test Statistical Category <sup>2</sup>	One-Way ANOV
	10%	25%	Median	75%	90%	Mean		
Pediatric (NB-13)	0.03	0.06	0.12	0.5	1	0.330904	0.01261	A
Young Adult (14-29)	0.03	0.06	0.12	0.5	1	0.333379	0.01352	A
Adult (30-64)	0.03	0.12	0.12	0.5	1	0.414097	0.00653	B
Geriatric (65+)	0.06	0.12	0.25	0.5	1	0.459822	0.00692	C

<sup>1</sup> Std Error uses a pooled estimate of error variance

<sup>2</sup> Different letters represent statistically different groups. Same letters represent groups that are statistically similar.

## CONCLUSIONS

- Tigecycline demonstrated an MIC<sub>90</sub> of ≤1 mcg/ml for all organisms and age groups.
- Tigecycline demonstrated statistically different in vitro activity among the various age groups for all study organism combined (p<0.001). Although within this same combined organism group no statistical difference in activity was noted between the pediatric and young adult age groups (p=0.8935, not shown in tables).
- An Analysis of Variance demonstrated varying activity of tigecycline among the four age groups for the *Enterobacteriaceae* and *Acinetobacter* spp (p<0.001) while showing more consistent activity across age groups for *Haemophilus* and the Gram-positive species (p-values 0.063 - 0.4908).
- A paired t-Test demonstrated varied degrees of similar activity of tigecycline among age groups within species and organism groups. Tigecycline activity was more consistent in Pediatric/Young Adult age groups in most species while the Adult/Geriatric populations were often paired with similar activity.
- While the activity of tigecycline varied slightly among age groups within different organism groups and species, the overall activity of tigecycline was consistently within the FDA susceptible ranges for >90% of all organism groups and species (where breakpoints exist) and in all age groups.

Table 3. Statistical Analysis of Tigecycline MIC values by Age Groups Categorized by Individual Species or Family Groups.

	Quartile MIC (mcg/mL)						t-Test Statistical Category <sup>2</sup>	One-Way ANOVA
	10%	25%	Median	75%	90%	Mean		
<i>Enterobacteriaceae</i>								
Pediatric (NB-13)	0.12	0.25	0.5	0.5	1	0.5635	0.02593	A
Young Adult (14-29)	0.12	0.12	0.25	0.5	1	0.5257	0.02697	A
Adult (30-64)	0.12	0.25	0.5	0.5	1	0.6499	0.01242	B
Geriatric (65+)	0.12	0.25	0.5	0.5	1	0.672	0.01227	B
<i>Enterococcus</i> spp								
Pediatric (NB-13)	0.03	0.06	0.06	0.12	0.12	0.0935	0.00537	A B
Young Adult (14-29)	0.03	0.06	0.06	0.12	0.12	0.1038	0.00556	A
Adult (30-64)	0.03	0.06	0.06	0.12	0.12	0.0905	0.00216	B
Geriatric (65+)	0.03	0.06	0.06	0.12	0.12	0.0884	0.00219	B
<i>Haemophilus</i> spp								
Pediatric (NB-13)	0.06	0.12	0.12	0.25	0.25	0.1994	0.0093	A
Young Adult (14-29)	0.06	0.12	0.12	0.25	0.5	0.2027	0.01509	A
Adult (30-64)	0.06	0.12	0.12	0.25	0.5	0.1951	0.0079	A
Geriatric (65+)	0.06	0.12	0.12	0.25	0.5	0.2132	0.0089	A
<i>Acinetobacter</i> spp								
Pediatric (NB-13)	0.06	0.06	0.12	0.5	1	0.3498	0.05073	A
Young Adult (14-29)	0.06	0.12	0.25	1	1	0.5581	0.04348	B
Adult (30-64)	0.06	0.12	0.5	1	1	0.5931	0.02077	B
Geriatric (65+)	0.06	0.12	0.5	1	1	0.6098	0.02339	B
<i>S. aureus</i>								
Pediatric (NB-13)	0.06	0.12	0.12	0.12	0.25	0.1271	0.00733	A B
Young Adult (14-29)	0.06	0.12	0.12	0.12	0.25	0.1386	0.00695	A
Adult (30-64)	0.06	0.12	0.12	0.12	0.25	0.1481	0.00343	B
Geriatric (65+)	0.06	0.12	0.12	0.12	0.25	0.1437	0.00393	B
<i>S. pneumoniae</i>								
Pediatric (NB-13)	0.015	0.015	0.03	0.25	0.5	0.1922	0.01111	A
Young Adult (14-29)	0.015	0.015	0.03	0.25	1	0.2158	0.01986	A
Adult (30-64)	0.015	0.015	0.03	0.25	0.5	0.1746	0.0082	A
Geriatric (65+)	0.015	0.03	0.06	0.25	0.5	0.1789	0.00965	A
Other Streptococci								
Pediatric (NB-13)	0.015	0.015	0.03	0.25	0.5	0.1922	0.01111	A
Young Adult (14-29)	0.015	0.015	0.03	0.25	1	0.2158	0.01986	A
Adult (30-64)	0.015	0.015	0.03	0.25	0.5	0.1746	0.0082	A
Geriatric (65+)	0.015	0.03	0.06	0.25	0.5	0.1789	0.00965	A

<sup>1</sup> Std Error uses a pooled estimate of error variance

<sup>2</sup> Different letters represent statistically different groups within the same species or organism group. Same letters represent groups that are statistically alike.